Since the Chinese biopharma boom started in the late-2000s, Chinese biotechs have seen in-licensing as a shortcut to establishing their own portfolios…
Yoji Yuki, CEO of Japanese regenerative medicine company UniBio, recalls the roots behind the venture and its plant-based technology. He also sets out…